The Quiet Influence in Your Prescription: Why Ghana’s Doctors May Not Be the Final Decision-Makers Anymore

Let me ask you something that might make you uncomfortable. The next time a doctor writes you a prescription, how do you know that the medicine on that paper is truly the best one for you? Not just a good one. Not just a safe one. The best one. Most of us do not ask that question. We trust. We have been raised to trust the white coat. But what if I told you that behind that white coat, there is a quiet force that most patients never see, and that force is slowly changing how decisions are made in our hospitals and clinics? I am not talking about corruption. I am not talking about lazy doctors. I am talking about something much more subtle and much harder to fight. I am talking about influence. The kind that creeps in through repeated visits, friendly conversations, free samples, and the simple fact that a human being remembers a name they hear often.

Let me paint you a picture. On most days in Accra, everything looks normal. Patients line up. Doctors consult. Prescriptions are written. Pharmacies dispense. Life moves on. But beneath that routine, something is shifting. Pharmaceutical representatives, the people who work for drug companies, move through hospital corridors from Osu to Tema, from Korle Bu to smaller district facilities, with quiet familiarity. They are not strangers. They are expected. In many cases, they are welcomed. They come from companies, some local but many foreign, including big manufacturing hubs in India and the United States. They come with products that doctors may not have deeply studied. They come with new molecules, new brands, all competing aggressively for attention in a crowded market. And they come with strategy.

The conversations are brief but deliberate. A new drug is introduced. Its advantages are highlighted, always highlighted, because nobody brings a drug to a doctor and talks about its weaknesses. Samples are left behind. A follow-up visit is scheduled. Over time, that product becomes familiar. Not because the doctor read ten clinical trials and concluded it was the best. But simply because they have seen it, heard about it, touched it, maybe even given a sample to a patient who came back with a good report. And familiarity, in medicine, is powerful. In fact, it is so powerful that researchers at Kwame Nkrumah University of Science and Technology documented this years ago according to the editorial by Accra Street Journal. They found that pharmaceutical representatives were visiting doctors regularly, offering samples and gifts, building relationships that went beyond the consulting room. And health professionals admitted that these interactions could influence what they prescribe, even as they insisted their judgment remained intact.

Now, that was years ago. Fifteen years later, there has been no major national reassessment. No updated data to measure how deep this system now runs. No public registry of financial relationships between doctors and drug companies. No consistent monitoring of prescribing patterns. What was once a warning has become a blind spot. And that is dangerous, not because doctors are careless, but because the system they operate in has quietly shifted. In theory, every prescription should be grounded in evidence. Clinical trials. Treatment guidelines. Patient history. In practice, another layer has been added. One driven by access, repetition, and commercial pressure.

Here is the thing that keeps me up at night. A doctor does not need to be corrupt to be influenced. They only need to be human. Repeated exposure to a drug name makes it easier to recall. A familiar representative becomes a trusted source. A product discussed every week begins to feel safer than one rarely mentioned. Over time, that subtle shift can determine what ends up on your prescription pad. And when those drugs come from a complex global supply chain, manufactured abroad, marketed aggressively, and introduced rapidly into our local markets, the risks multiply. Ghana’s regulatory framework is not built for this level of complexity. The Food and Drugs Authority is responsible for approving medicines and overseeing promotion. They vet advertisements and monitor safety reports. But the day-to-day interactions that shape prescribing decisions happen outside their direct line of sight. There is limited visibility into how often doctors meet pharmaceutical representatives. Limited oversight of sponsored medical education. Limited tracking of how new drugs, especially those from international manufacturers, are adopted in clinical practice.

This is not about pointing fingers at the FDA. They do their job with limited resources. But the truth is that a critical part of our decision-making ecosystem operates without continuous scrutiny. And that creates space. And that space is where risk grows. Because not every drug aggressively promoted is fully understood by every prescriber. Not every new product has long-term safety data specifically for the Ghanaian population. Not every recommendation shared in a ten-minute meeting reflects the full scientific picture. Yet prescriptions are written. Patients take the medicines. And the outcomes, whether good or bad, are absorbed quietly into the system. No alarms sound. No warning appears on the paper handed to you. There is no visible signal that your prescription may have been shaped by forces beyond the consultation room. Everything looks routine. Until it is not.

Let me connect this to the bigger economic picture we have been discussing in recent columns. We talk about the cedi, about inflation, about the IMF review, about AI and one million coders. But what is the point of a growing economy if your medicine is chosen based on marketing muscle rather than medical evidence? What is the point of a stable cedi if you are paying for a branded drug that costs three times more than a generic that would work just as well, simply because your doctor has met that company’s representative eight times this year? Healthcare costs rise when prescribing is driven by commercial presence. Antibiotics risk being overused, feeding a global resistance crisis that is already killing people. Treatment decisions become less consistent and harder to audit. And most importantly, trust begins to erode.

That is the quietest crisis of all. Because once you start wondering whether your doctor is truly independent, the entire system begins to crack. And right now, the silence around this issue is part of the problem. Professional bodies like the Ghana Medical Association have not enforced a comprehensive, binding national framework governing interactions between doctors and drug companies. Disclosure of financial relationships is not standard practice. Patients are not informed if a drug being prescribed is heavily promoted within the system. So the burden falls on individuals. Doctors must self-regulate. Patients must trust. Regulators must react after the fact. That is not a stable model. That is a waiting game.

What makes this situation particularly dangerous is not a single bad actor or a single unsafe drug. It is the quiet normalisation of influence in a system that depends on objectivity. And this is where you, the ordinary Ghanaian, must wake up. Not with fear. Not with anger. But with curiosity. The next time you visit a hospital or a clinic, ask questions. It does not have to be aggressive. You can simply say, “Doctor, is there a cheaper generic version of this medicine?” Or, “Doctor, how did you come to know about this particular drug?” Or even, “Are there any other options we can consider?” These are not disrespectful questions. They are the questions of a patient who understands that healthcare is a partnership, not a command.

I am not writing this to make you suspicious of every doctor. Most of our doctors are hardworking, honest people who genuinely want to help. But they are also human. And they work in a system where pharmaceutical companies spend millions of cedis to get their products noticed. That is the reality. The question is not whether influence exists. The question is how much of our healthcare system has already quietly adapted to it. And that leads to a question every patient should now feel comfortable asking, without fear and without hesitation: Is this medicine being prescribed because it is the best option for me, or because it is the most familiar one to you? Until that question has a clear, transparent answer, the system remains exposed. And the risk remains real. So do not be afraid to ask. Your health is too important for silence.

Source Used: Accra Street Journal - Health